|Day Low/High||185.69 / 186.87|
|52 Wk Low/High||114.27 / 186.91|
Investors must understand that the narrative around trade with China has evolved as the two sides work on a 'Phase One' mini-trade deal, but this is about much more than that.
These stocks are priced for total imperfection. That's just what you want.
The aging population is creating a massive tailwind for companies that provide cutting-edge health care.
Right now, AbbVie is the best way to capitalize on the moment and on the future.
* Only three of eleven S&P sectors are viewed as attractive * I am in a risk off state of mind. Back in 2015 I instituted a new regular feature called "Sectors," in which I periodically offered my short-term (6-12 months) price outlook for each of t...
No company is safe from the litigation risk tied to the drug epidemic, but Johnson & Johnson may be one of the few guaranteed to survive.
EOLS appears to have formed a small triangle pattern the past few weeks and a breakout is likely before reaching the apex.
ABBV has a positive earnings-per-share growth, an expanding price-to-earnings multiple and dividends that could result in annual shareholder returns well above 20%.
In July, the RMPIA climbed 0.6%, bringing its year-to-date return to just over 21%.
AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.
The Fed chairman's news conference threw markets for a loop with hawkish words that did not support the Fed's dovish actions.
Here are my five rules for handling earnings season.
Here's my take on the M&A landscape as well as my own speculation of some possible logical buyout targets.
There are a number of RMPIA companies that will be beneficiaries of Back to School and holiday spending.
Stocks see a nice surge on the open on optimism around trade talks resuming between the U.S. and China, although negotiations will be ongoing for many months and no permanent resolution seems on the horizon. The U.S. PMI Manufacturing Index also cam...
It is good to be sitting in for Doug Kass here on The Daily Diary as we open trading in the second half of 2019. June ended on an up note as all the major indices drifted up last week to close out the month and quarter. The market did an admirable j...
Watch the Russell 2000, housing activity, and mergers and acquisitions.
The drop in AbbVie's stock price following revelation of its plans to buy Allergan provides a way to hit a solid investment single using a buy-write options strategy.
Despite the financial positivity, many analysts warn the deal could have hiccups ahead.
The deal makes sense for growth - and for Allergan shareholders - but now the price and uncertainty make this stock hard to swallow.
With no other bidder expected to emerge, this is a high risk arbitrage play.
PFE was ready to pay $160 billion until U.S. regulators blocked the deal.
The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.